Collaborative Cross of the Microbiome and Metabolic Disease
Collaborative Cross of the Microbiome and Metabolic Disease
批准号:
9038121
负责人:
Federico E Rey
金额:
$44.51万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-23 至 2020-08-31
关键词:
AffectAntimicrobial EffectBacteriaBile AcidsBile fluidBindingBiochemicalBiologicalBreedingCholesterolChromosome MappingCollectionCommunicationControl LocusDevelopmentDiabetes MellitusDietDisease susceptibilityDuodenumEatingEnergy MetabolismEnzymesFamilyFat-Soluble VitaminFatty acid glycerol estersFoodG-Protein-Coupled ReceptorsGallbladderGenesGeneticGenetic VariationGenomicsGenotypeGnotobioticHealthHepaticHeterozygoteHormonesHumanInbreedingIndividualInsulin ResistanceIntegration Host FactorsIntestinal MotilityIntestinesLinkLipidsLiverMammalian GeneticsMediatingMetabolicMetabolic DiseasesMetabolismMetagenomicsMicrobeModelingMusNon-Insulin-Dependent Diabetes MellitusNuclear ReceptorsNutritionalObesityOrganismOutcomePathway interactionsPhenotypePhysiologicalPhysiologyPlasmaPlayPopulationPredispositionProbioticsProcessProductionQuantitative Trait LociRecombinantsResolutionResourcesRoleSamplingSignal TransductionSucroseSystemTaxonToxic effectTransplantationabsorptionbaseblood glucose regulationcohortcomplex biological systemsdehydrogenationdehydroxylationdesignfeedinggenetic analysisgut microbiotalipid metabolismmetabolomicsmicrobialmicrobial communitymicrobiomenext generationnovelnutritionpreventpublic health relevancerRNA Genesresponsetrait
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The collections of microbes (i.e., microbiota) that inhabit the human intestine have profound effects on development, physiology and health. Alterations in the gut microbiota contribute to metabolic disorders including obesity and diabetes. Gut microbes affect our physiology at least in part by metabolizing bile acids (BAs). BAs are key nodes of metabolic communication between gut microbes and the host; they are synthesized in the host liver, have antimicrobial effects, facilitate the absorption of lipids, andact as hormones to modulate glucose homeostasis, lipid metabolism, energy expenditure, and intestinal motility. Gut microbes in turn metabolize BAs and regulate their synthesis and their influence on host physiology. However, the genes that modulate the composition of the gut microbiota and abundance of individual species of BAs remain largely unknown. We propose to combine the power of the Diversity Outbred (DO) mouse panel, a newly developed resource that contains as much genetic variation as the human population, with biochemical analyses of BAs and gut microbiota profiling to identify genes and pathways that modulate gut microbial composition and abundance of BAs, and are associated with disease susceptibility. The phenotypic diversity and high-resolution genetic mapping of the DO mice will direct our use of select gnotobiotic hosts of different genetic backgrounds to experimentally validate the contributions of these genes and pathways on gut microbial composition, abundance of BAs and disease susceptibility. The proposed studies are based on three central hypotheses: (i) host genetic variation alters microbiota composition; (ii) differences in microbiota composition result in changes in BA composition and BA-dependent host signaling; and (iii) altered BA signaling contributes to the development of metabolic disease. Our preliminary studies on a small cohort of DO mice have revealed an extraordinary level of phenotypic diversity of diabetes-related traits, fecal BAs and gut microbiota composition in response to a prolonged feeding of a "western-style" high-fat/high-sucrose diet. Our collective expertise in gnotobiotics and gut microbiome (Rey), nutrition, obesity and diabetes (Attie, Keller), metabolomics (Wang) and statistical genetics (Broman) will enable the discovery of novel genetically-driven host-microbe interactions that modulate the development of diet-induced metabolic disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Model-guided design of next-generation bacterial therapeutics to treat cardiovascular disease
-
批准号:10249177
-
项目类别:
-
资助金额:$66.72万
-
财政年份:2020
-
负责人:Federico E Rey
-
依托单位:
Model-guided design of next-generation bacterial therapeutics to treat cardiovascular disease
-
批准号:10044931
-
项目类别:
-
资助金额:$69.75万
-
财政年份:2020
-
负责人:Federico E Rey
-
依托单位:
Model-guided design of next-generation bacterial therapeutics to treat cardiovascular disease
-
批准号:10453661
-
项目类别:
-
资助金额:$66.16万
-
财政年份:2020
-
负责人:Federico E Rey
-
依托单位:
Administrative Supplement: Model-guided design of next-generation bacterial therapeutics to treat cardiovascular disease
-
批准号:10838889
-
项目类别:
-
资助金额:$17.5万
-
财政年份:2020
-
负责人:Federico E Rey
-
依托单位:
Model-guided design of next-generation bacterial therapeutics to treat cardiovascular disease
-
批准号:10624465
-
项目类别:
-
资助金额:$64.15万
-
财政年份:2020
-
负责人:Federico E Rey
-
依托单位:
Collaborative Cross of the Microbiome and Metabolic Disease
-
批准号:9545554
-
项目类别:
-
资助金额:$40.27万
-
财政年份:2015
-
负责人:Federico E Rey
-
依托单位:
海外基金